Partners.
Together with our partners, we make the GARD® assays available for in-vitro toxicology testing in your region.

Together with our partners, we make the GARD® assays available for in-vitro toxicology testing in your region.
Become a partner of SenzaGen and get access to the latest tech development in alternative testing. You will reach new customers & markets and get exclusive support to help your business grow.
If you want more information or have further questions, please email us.
SenzaGen is working with some of the best specialist contract research organizations (CROs) and distributors in Europe, North America and Asia-Pacific. For consultancy and quote, please contact one of them.
SenzaGen AB – Sweden
Head Quarter and Lab services
Dr Andy Forreryd | Key Account Manager & Scientific Liason
Office Phone: +46 46 2756200
Direct: +46 734 331777
Email
Eurofins BioPharma Product Testing – Germany
Dr Helge Gehrke | In vitro Pharmacology and Toxicology
Direct: + 49 89 899 650-0
Email
XCellR8 – UK
Dr Carol Treasure | Co-founder/Managing Director
Direct: + 44 1925 607 134
Email
Charles River Laboratories – The Netherlands
Walter Westerink | Study Director Discovery, Safety Assessment
Direct: + 31 (0)73 640 67 00
Email
Danish Technological Institute – Denmark
Helle Stendahl Andersen | Business Manager, Laboratory for Chemistry and Microbiology
Direct: +45 72 20 24 21
Email
EUROSAFE – France
Direct: +33 (0)2 99 23 46 46
Email
GenEvolutioN – France
Francis Finot | Chairman)
Direct: +33 (0)6 65 75 94 78
Email
PKDerm – France
Hanan Osman-Ponchet | CEO
Direct: +33 6 70 25 28 56
Email
VitroScreen – Italy
Direct: +39 02 89077608
Email
SenzaGen Inc – North Carolina, US
US Subsidiary
SenzaGen Sales representative
Joshua Schmidt | Business Development Director-Americas
Direct: +1 651.440.5691
Email
Burleson Research Technologies – US
Florence Burleson | Co-founder, Director
Direct: + 1 919 719 2500
Email
MB Research Labs – US
Barbara Kweder | Client Services
Direct: +1 215-536-4110
Email
Guangzhou Chn-Alternative Biotechnology Co., Ltd. – China
Dr. Shujun Cheng | CEO
Email
Woo Jung BSC – South Korea
Sera Kim |
Direct: + 82 31 888 9372
Email
To further explore new application areas for the GARD technology platform, SenzaGen is working closely with scientific institutions and industrial partners.
The technology collaboration with AstraZeneca focuses on the development of respiratory tests. The project received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 756014.
Contact us to explore potential collaborations.